Postmarketing Study End Of Usefulness Must Be Confirmed By FDA

Industry must continue to submit status reports on terminated postmarketing drug studies until FDA concurs the studies will provide no more useful information, under a proposed revision to postmarketing study status annual reporting regs.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet